RPRX
NasdaqRoyalty Pharma plc
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$2.3B
2021
$2.2B
2022
$2.4B
2023
$2.3B
2024
$2.4B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$2.4B
Net Income$1.3B
Gross Profit—
Oper Income$1.6B
EPS (dil)$1.78
Rev/sh$6.13
FCF/sh—
Book/sh$25.03
Gross M—
Oper M65.6%
Profit M55.7%
FCF M—
ROE13.6%
ROA6.7%
ROIC6.7%
R&D/Rev19.0%
Rev Y/Y5.1%
Rev 3Y CAGR2.1%
EPS Y/Y-6.8%
EPS 3Y CAGR161.1%
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y-5%
Current Ratio2.40
Quick Ratio—
Debt/Eq0.96
Int Coverage5.1×
Net Debt$8.7B
Total Debt$9.3B
Cash & Eq$618.7M
Total Assets$19.6B
Oper CF$2.5B
Capex—
Free CF—
Buybacks$1.2B
Equity$9.7B
Liabilities$9.9B
Shs Outstand0.39B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.3B | $2.2B | $2.4B | $2.3B | $2.4B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $1.4B | $307.1M | $1.5B | $1.3B | $1.6B |
| Net Income | $1.2B | $230.0M | $1.7B | $1.3B | $1.3B |
| Diluted EPS | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
| Operating Cash Flow | $2.0B | $2.1B | $3.0B | $2.8B | $2.5B |
| Free Cash Flow | — | — | — | — | — |
COMMUNITY · $RPRX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.